Cingulate Inc.

NASDAQ:CING

Biotechnology

Healthcare
$5.11 -0.95%

-$0.05 today

Market cap
$76.46M
Beta
-0.91
P/E (TTM)
-1.0
EPS (TTM)
-$5.10
52W Low $3.16High $11.89

Volume 0.95M

Average 0.46M

CING Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Cingulate Inc.NASDAQ: CING

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity rises 218.1% from a year ago

Total equity stood at $18.86M at the end of Q1 FY2026, up 218.1% from a year earlier and up 651.9% from the prior quarter. Over 3 fiscal years it compounded at -13.5% a year.

Context

  • Total equity amounted to 61.1% of total assets at the end of Q1 FY2026, up 13.6 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +218.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$18.86M+651.9% QoQ
Last fiscal yearDec 2025
$2.51M-66.3% YoY
Year agoMar 2025
$5.93M+218.1% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+218.1%——
1 year-66.3%——
3-year CAGR-13.5%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
2.51M USD
Year-over-year change
-66.3%
4-year CAGR
-41.1%

Total Equity vs competitors

How CING compares with its peers on the latest reported figures

  • CING's Mar 2026 total equity of $18.86M is the highest of the 2 companies compared; the peer median is $9.18M.
  • Its year-over-year change of +218.1% is the lowest of 2, against a peer median of +691.9%.
  • Total equity amounts to 61.1% of total assets for CING, versus a peer median of 84.5%.
CING Competitors Peer median
Total Equity for CING and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CINGCingulate Inc.Mar 2026$18.86M +218.1%-13.5%61.1%
LIXTLixte Biotechnology Holdings, Inc.Mar 2026$9.18M +691.9%+28.5%84.5%
Peer median (excluding CING) $9.18M+691.9%+28.5%84.5%

Competitors are the stored peer set for CING. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents16.49M5.36M52.42K12.21M10.95M
Short-term Investments9330000
Net Receivables690.25K234.43K14.62K26.33K8.01K
Inventory0100.34K000
Other Current Assets1.7M1.64M490.86K368.29K80.08K
Total Current Assets18.88M7.87M578.59K12.66M12.01M
Property, Plant & Equipment (Net)4M3.54M2.91M2.2M3.07M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets1.36B5.91B000
Other Non-current Assets(1.36B)(5.91B)000
Total Non-current Assets4M3.54M2.91M2.2M3.07M
Total Assets22.89M11.41M3.49M14.86M15.07M
Account Payables264.69K762.36K5.2M1.27M2.04M
Short-term Debt310.69K5M3M2.53M6.3M
Tax Payables00120.57K200K0
Deferred Revenue601.3K0000
Other Current Liabilities(336.67K)719.01K593.02K355.48K455.18K
Total Current Liabilities1.18M7.01M10.23M4.97M10.31M
Long-term Debt0002.44M1.15M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities866.04K510.24K135.1K2.44M2.25M
Total Liabilities2.04M7.52M10.36M7.41M12.56M
Common Stock1.13K6110340725
Retained Earnings(51.73M)(69.41M)(92.94M)(108.49M)(132.38M)
Accumulated OCI1650000
Other Stockholders Equity00000
Minority Interest00000
Total Equity20.84M3.88M(6.87M)7.46M2.51M
Total Debt1.19M5.87M3.51M5.1M8.79M
Net Debt(15.3M)509.77K3.46M(7.11M)(2.17M)

Cingulate Inc.

NASDAQ:CING

Intrinsic Alpha fair value

Locked

Current Price

$5.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.